These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 32031683)

  • 21. IL-19 Contributes to the Development of Nonalcoholic Steatohepatitis by Altering Lipid Metabolism.
    Azuma YT; Fujita T; Izawa T; Hirota K; Nishiyama K; Ikegami A; Aoyama T; Ike M; Ushikai Y; Kuwamura M; Fujii H; Tsuneyama K
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation.
    Ganz M; Csak T; Szabo G
    World J Gastroenterol; 2014 Jul; 20(26):8525-34. PubMed ID: 25024607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet.
    Okushin K; Tsutsumi T; Ikeuchi K; Kado A; Enooku K; Fujinaga H; Yamauchi N; Ushiku T; Moriya K; Yotsuyanagi H; Koike K
    PLoS One; 2020; 15(8):e0234750. PubMed ID: 32785220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis.
    Asano T; Watanabe K; Kubota N; Gunji T; Omata M; Kadowaki T; Ohnishi S
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1669-76. PubMed ID: 19788607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease.
    Kim TH; Banini BA; Asumda FZ; Campbell NA; Hu C; Moser CD; Shire AM; Han S; Ma C; Krishnan A; Mounajjed T; White TA; Gores GJ; LeBrasseur NK; Charlton MR; Roberts LR
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G333-G344. PubMed ID: 32683952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deceleration of liver regeneration by knockdown of augmenter of liver regeneration gene is associated with impairment of mitochondrial DNA synthesis in mice.
    Han LH; Dong LY; Yu H; Sun GY; Wu Y; Gao J; Thasler W; An W
    Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(2):G112-22. PubMed ID: 25977511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
    Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.
    Hou X; Yin S; Ren R; Liu S; Yong L; Liu Y; Li Y; Zheng MH; Kunos G; Gao B; Wang H
    Hepatology; 2021 Jul; 74(1):116-132. PubMed ID: 33236445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gender differences in diet-induced steatotic disease in Cyp2b-null mice.
    Heintz MM; McRee R; Kumar R; Baldwin WS
    PLoS One; 2020; 15(3):e0229896. PubMed ID: 32155178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression.
    Sansilvestri Morel P; Duvivier V; Bertin F; Provost N; Hammoutene A; Hubert EL; Gonzalez A; Tupinon-Mathieu I; Paradis V; Delerive P
    PLoS One; 2022; 17(2):e0263828. PubMed ID: 35148334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
    Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
    Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
    Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
    World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model.
    Hayashida M; Hashimoto K; Ishikawa T; Miyamoto Y
    Int J Exp Pathol; 2019 Apr; 100(2):72-82. PubMed ID: 30887659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice.
    Fuchs CD; Radun R; Dixon ED; Mlitz V; Timelthaler G; Halilbasic E; Herac M; Jonker JW; Ronda OAHO; Tardelli M; Haemmerle G; Zimmermann R; Scharnagl H; Stojakovic T; Verkade HJ; Trauner M
    Hepatology; 2022 Jan; 75(1):125-139. PubMed ID: 34387896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice.
    Honda T; Ishigami M; Luo F; Lingyun M; Ishizu Y; Kuzuya T; Hayashi K; Nakano I; Ishikawa T; Feng GG; Katano Y; Kohama T; Kitaura Y; Shimomura Y; Goto H; Hirooka Y
    Metabolism; 2017 Apr; 69():177-187. PubMed ID: 28285648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
    Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
    J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease.
    Rana R; Shearer AM; Fletcher EK; Nguyen N; Guha S; Cox DH; Abdelmalek M; Wang Y; Baleja JD; Covic L; Kuliopulos A
    Mol Metab; 2019 Nov; 29():99-113. PubMed ID: 31668396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression.
    Azzu V; Vacca M; Kamzolas I; Hall Z; Leslie J; Carobbio S; Virtue S; Davies SE; Lukasik A; Dale M; Bohlooly-Y M; Acharjee A; Lindén D; Bidault G; Petsalaki E; Griffin JL; Oakley F; Allison MED; Vidal-Puig A
    Mol Metab; 2021 Jun; 48():101210. PubMed ID: 33722690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.